Novo Nordisk A/S - Asset Resilience Ratio
Novo Nordisk A/S (NOVO-B) has an Asset Resilience Ratio of 0.09% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Novo Nordisk A/S (NOVO-B) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2001–2025)
This chart shows how Novo Nordisk A/S's Asset Resilience Ratio has changed over time. See Novo Nordisk A/S net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Novo Nordisk A/S's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Novo Nordisk A/S market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Dkr0.00 | 0% |
| Short-term Investments | Dkr498.00 Million | 0.09% |
| Total Liquid Assets | Dkr498.00 Million | 0.09% |
Asset Resilience Insights
- Limited Liquidity: Novo Nordisk A/S maintains only 0.09% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Novo Nordisk A/S Industry Peers by Asset Resilience Ratio
Compare Novo Nordisk A/S's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 7.18% |
|
CSPC Pharmaceutical Group Limited
F:CVG |
Drug Manufacturers - General | 4.64% |
|
Aurora Optoelectronics Co Ltd
SHG:600666 |
Drug Manufacturers - General | 5.89% |
|
Shandong Keyuan Pharmaceutical Co. Ltd. A
SHE:301281 |
Drug Manufacturers - General | 6.44% |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3 |
Drug Manufacturers - General | 10.10% |
|
Pfizer Inc
NYSE:PFE |
Drug Manufacturers - General | 7.18% |
|
Merck & Company Inc
NYSE:MRK |
Drug Manufacturers - General | 14.06% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
Annual Asset Resilience Ratio for Novo Nordisk A/S (2001–2025)
The table below shows the annual Asset Resilience Ratio data for Novo Nordisk A/S.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.09% | Dkr498.00 Million ≈ $77.92 Million |
Dkr542.90 Billion ≈ $84.94 Billion |
-2.20pp |
| 2024-12-31 | 2.29% | Dkr10.65 Billion ≈ $1.67 Billion |
Dkr465.80 Billion ≈ $72.88 Billion |
-2.75pp |
| 2023-12-31 | 5.04% | Dkr15.84 Billion ≈ $2.48 Billion |
Dkr314.49 Billion ≈ $49.20 Billion |
-4.74pp |
| 2022-12-31 | 9.77% | Dkr23.57 Billion ≈ $3.69 Billion |
Dkr241.26 Billion ≈ $37.75 Billion |
+0.78pp |
| 2021-12-31 | 8.99% | Dkr17.48 Billion ≈ $2.74 Billion |
Dkr194.51 Billion ≈ $30.43 Billion |
+0.19pp |
| 2020-12-31 | 8.80% | Dkr12.76 Billion ≈ $2.00 Billion |
Dkr144.92 Billion ≈ $22.67 Billion |
-3.52pp |
| 2019-12-31 | 12.32% | Dkr15.47 Billion ≈ $2.42 Billion |
Dkr125.61 Billion ≈ $19.65 Billion |
-1.80pp |
| 2018-12-31 | 14.12% | Dkr15.64 Billion ≈ $2.45 Billion |
Dkr110.77 Billion ≈ $17.33 Billion |
-6.55pp |
| 2017-12-31 | 20.67% | Dkr21.16 Billion ≈ $3.31 Billion |
Dkr102.36 Billion ≈ $16.01 Billion |
-0.55pp |
| 2016-12-31 | 21.22% | Dkr20.70 Billion ≈ $3.24 Billion |
Dkr97.54 Billion ≈ $15.26 Billion |
-1.07pp |
| 2015-12-31 | 22.29% | Dkr20.46 Billion ≈ $3.20 Billion |
Dkr91.80 Billion ≈ $14.36 Billion |
+1.65pp |
| 2014-12-31 | 20.64% | Dkr15.90 Billion ≈ $2.49 Billion |
Dkr77.06 Billion ≈ $12.06 Billion |
+0.07pp |
| 2013-12-31 | 20.57% | Dkr14.47 Billion ≈ $2.26 Billion |
Dkr70.34 Billion ≈ $11.00 Billion |
-3.95pp |
| 2012-12-31 | 24.52% | Dkr16.11 Billion ≈ $2.52 Billion |
Dkr65.67 Billion ≈ $10.27 Billion |
-2.53pp |
| 2011-12-31 | 27.05% | Dkr17.50 Billion ≈ $2.74 Billion |
Dkr64.70 Billion ≈ $10.12 Billion |
+0.91pp |
| 2010-12-31 | 26.14% | Dkr16.05 Billion ≈ $2.51 Billion |
Dkr61.40 Billion ≈ $9.61 Billion |
+2.71pp |
| 2009-12-31 | 23.43% | Dkr12.83 Billion ≈ $2.01 Billion |
Dkr54.74 Billion ≈ $8.56 Billion |
+3.35pp |
| 2008-12-31 | 20.08% | Dkr10.18 Billion ≈ $1.59 Billion |
Dkr50.73 Billion ≈ $7.94 Billion |
+4.63pp |
| 2007-12-31 | 15.45% | Dkr7.38 Billion ≈ $1.16 Billion |
Dkr47.80 Billion ≈ $7.48 Billion |
+4.03pp |
| 2006-12-31 | 11.42% | Dkr5.10 Billion ≈ $798.32 Million |
Dkr44.70 Billion ≈ $6.99 Billion |
-0.56pp |
| 2005-12-31 | 11.98% | Dkr5.02 Billion ≈ $785.10 Million |
Dkr41.90 Billion ≈ $6.55 Billion |
+1.39pp |
| 2004-12-31 | 10.58% | Dkr3.99 Billion ≈ $624.21 Million |
Dkr37.70 Billion ≈ $5.90 Billion |
+1.60pp |
| 2003-12-31 | 8.98% | Dkr3.10 Billion ≈ $484.74 Million |
Dkr34.49 Billion ≈ $5.40 Billion |
+3.45pp |
| 2002-12-31 | 5.54% | Dkr1.74 Billion ≈ $272.41 Million |
Dkr31.45 Billion ≈ $4.92 Billion |
+0.70pp |
| 2001-12-31 | 4.84% | Dkr1.40 Billion ≈ $218.28 Million |
Dkr28.83 Billion ≈ $4.51 Billion |
-- |
About Novo Nordisk A/S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products i… Read more